New York, June 2, 2026, 08:02 (EDT)
- Arcturus was quoted at $7.81 in pre-market trading, up 0.5% from Monday’s close.
- The next company-specific events are a Jefferies healthcare presentation on June 4 and the annual meeting on June 5.
- Investors are still weighing a smaller revenue base, Phase 2 trial execution and cash runway.
Arcturus Therapeutics Holdings Inc. edged higher before Tuesday’s Nasdaq open, a small rebound after a weaker Monday, as traders looked past thin early trading to two company events later this week. Public.com data showed ARCT at $7.81 at 8:00 a.m. ET in pre-market trading, up 0.51% from the previous market-session close of $7.77; pre-market trading means orders before the regular 9:30 a.m. open and often comes with light volume.
The regular session was still ahead. June 2 is not listed among Nasdaq’s 2026 U.S. equity market holidays, and the next scheduled full closure is Juneteenth on June 19.
Why it matters now is the calendar. Arcturus is due to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 4, at 9:20 a.m. ET, giving management a near-term slot to update investors on its pipeline and capital plans.
The shares slipped 1.89% to $7.77 on Monday even as the S&P 500 rose 0.26% and the Dow Jones Industrial Average added 0.09%, according to MarketWatch data. That left the stock still trading close to the lower end of a 52-week range that has run from about $5.85 to more than $24.
Arcturus is a messenger RNA, or mRNA, company; mRNA is the genetic instruction material cells use to make proteins. Its current investor story rests less on COVID vaccine economics and more on rare-disease programs in cystic fibrosis and ornithine transcarbamylase deficiency, a rare metabolic liver disorder.
The latest quarterly filing showed the shift clearly. Revenue fell to $2.1 million in the first quarter from $29.4 million a year earlier, while the net loss widened to $27.0 million, or 95 cents a share; cash, cash equivalents and restricted cash stood at $213.4 million at March 31.
Chief Executive Joseph Payne said the company had begun enrolling a 12-week cystic fibrosis Phase 2 study — a mid-stage human trial — earlier than planned and remained “committed to advancing our inhaled mRNA therapy.” CFO Dennis Mulroy pointed to a “strong balance sheet and runway,” using the biotech term for how long cash is expected to fund operations. Arcturus Therapeutics, Inc.
The revenue fall was tied partly to collaboration timing. The 10-Q showed CSL Seqirus collaboration revenue of $610,000 in the quarter, down from $25.5 million a year earlier, while BARDA grant revenue fell to $891,000 from $3.9 million; BARDA is the U.S. Biomedical Advanced Research and Development Authority.
The competitive bar is high. Vertex Pharmaceuticals, the dominant cystic-fibrosis name, reported $424.4 million in first-quarter revenue from Alyftrek and $2.35 billion from older CF drug Trikafta, while Arcturus is still trying to show ARCT-032 can matter in patients who lack good modulator options.
That is the opening Arcturus is aiming at. The Cystic Fibrosis Foundation says CFTR modulators are effective only in people with specific mutations, and Arcturus’ then-chief medical officer Juergen Froehlich said last October that Class I cystic fibrosis patients “do not respond” to available CFTR modulator therapy. Cystic Fibrosis Foundation
There is also a governance date. The company’s annual meeting is set for Friday, June 5, at 9:00 a.m. Pacific time, with shareholders voting on directors, executive pay on an advisory basis and the ratification of Deloitte as auditor.
But the risk is still clinical and financial. Arcturus said future capital needs are hard to forecast and that it expects more losses as it advances product candidates; if milestones slip, trial data disappoint or financing markets tighten, the company may need to scale back programs or raise capital on dilutive terms.
